Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Physicians & Staff

Firas Mourtada, MSE, Ph.D., D.ABR

Chief of Clinical Physics

Firas Mourtada, MSE, Ph.D., D.ABR, is the chief of clinical physics at the Helen F. Graham Cancer Center, where he oversees the delivery of radiation treatments by working side by side with a team of radiation oncologists, physicists, and dosimetrists to ensure patients receive the safest and most effective treatment for cancer. He is also responsible for seeking and integrating cutting-edge radiation oncology technologies into our health system.
Since joining ChristianaCare in 2011, Dr. Mourtada also has worked to establish initiatives for clinical trials at the Helen F. Graham Cancer Center as well as clinically oriented research in collaboration with the Center for Translational Cancer Research and within ChristianaCare’s Radiation Oncology Department. His own research work at ChristianaCare includes a National Institutes of Health-funded grant to investigate a novel dose calculation method for treatment planning of targeted radionuclide therapy. The results could help radiation oncologists better predict how tumors respond to such therapy and the likelihood of cancer recurring and spreading.

Dr. Mourtada has a master’s degree in biomedical engineering from The Johns Hopkins University in Baltimore. He earned his doctorate in radiation health from Johns Hopkins in 1997. He also completed a postdoctoral fellowship at the National Institute of Standards and Technology in Gaithersburg, Md.

Download Dr. Mourtada’s CV.

Selected Research

Summary of Published Work: https://www.researchgate.net/profile/Firas_Mourtada2?ev=prf_highl

Principal Investigator (15%), A Novel Dose Calculation Method for Targeted Radionuclide Therapy, R01 CA138986-01A2, NIH/NCI, 8/5/2010-7/31/2016, $978,495.

Principal Investigator, Evaluation of the Varian Eclipse AXB Dose Algorithm, Sponsored Research Agreement, Varian Medical Systems, 6/2011-12/2012, $20,000.

Co-Investigator (5%), Human Breast Cancer Stem Cell Surrogates, extension to R01 CA138239-01 ($3,053.539), NIH/NCI, Multi-PI- Cristofanilli/Reuben/Woodward, $599,556. 7/1/09-6/30/12.

MDACC Consortium Principal Investigator (2%), Idea Award, Army DOD BCRP BC073879, “Metabolic-Targeted Radionuclide Therapy for the Treatment of Breast Cancer” ($296,000).

MDACC Consortium Principal Investigator (10%), NIH SBIR Phase II proposal 2R44 CA105806-02 with Transpire, Inc., “Deterministic Radiotherapy Calculation Method” ($750,000), 9/2007-6/2011.

Co-Principal Investigator (5%), Development of radiolabeled serotonin transformation agent for imaging neuroendocrine tumors, SRA from Miyagi Clinic Sendai Medical Imaging Center. 6/07-6/09, ($247,000).

Principal Investigator (2%), Inverse Planning Software for Adaptive Intracavitary Brachytherapy, MDACC Technical Review Committee. 10/2006-6/2007 ($65,000).

Principal Investigator (10%), Adaptive Intracavitary Brachytherapy Applicator for Cervical Cancer MDACC Technical Review Committee. 9/2004-9/2005 ($30,000).

Principal Investigator (5%) Institutional Startup Funds, The University of Texas M. D. Anderson Cancer Center. 12/2002-12/2005, $175,000 ($58,333 /year).

Principal Investigator, Commissioning of BEBIG 106Ru/106Rh Eye Plaques: A Practical Clinical Procedure for US Hospitals, SRA from BEBIG. 6/06-6/07, ($10,000).

MDACC Co-Investigator, NIH SBIR Phase I with Transpire, Inc.: Deterministic Radiotherapy Calculation Method, 04/2005-09/2005, CA105806-01A1 ($100,000).

MDACC Principal Investigator, NIH SBIR Phase I with NoviMarte, Inc.: Multi-Purpose Radiopharmaceutical Synthesis Platform, HHSN261200522013C, 08/2005-3/2006, ($100,000).

Principal Investigator, Intravascular Brachytherapy Dosimetry Research, Advanced Cardiovascular Systems, Inc. SR2003-00008635HM 01, 4/7/2003-4/30/2004, ($21,500).

Principal Investigator, Dosimetric Evaluation of Pulsed Dose-rate Brachytherapy for Gynecological Cancer Treatment: A Monte Carlo Study, SRA from Nucletron. 4/04-8/05, ($60,000).

MDACC Principal Investigator, Development of Acuros Dose Engine for Brachytherapy, Radion Technologies SRA. 09/04-09/05 ($38,000).

Principal Investigator, TheraSight? Dosimetry Characterization, SRA from Theragenics Corp. (Period: 6 months, Amount: $7,000).